Lamotrigine Tablets, USP, 150 mg, 20,000-count bulk container, Manufactured by: Jubilant Cadista ...
FDA Drug Recall #D-1281-2020 — Class III — May 26, 2020
Recall Summary
| Recall Number | D-1281-2020 |
| Classification | Class III — Low risk |
| Date Initiated | May 26, 2020 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Jubilant Cadista Pharmaceuticals, Inc. |
| Location | Salisbury, MD |
| Product Type | Drugs |
| Quantity | 1,313,333 tablets |
Product Description
Lamotrigine Tablets, USP, 150 mg, 20,000-count bulk container, Manufactured by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, USA, For repackaging by: AvKare Inc., Pulaski, TN 38478, Bulk Shipment, NDC 59746-247-97.
Reason for Recall
Presence of Foreign Substance visually consistent with the silica granules present in the desiccant packs utilized during storage of the product.
Distribution Pattern
TN
Lot / Code Information
Lot #s 19P0437 & 19P0438, Exp. 09/30/2021.
Other Recalls from Jubilant Cadista Pharmaceuticals, Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0096-2023 | Class III | Prochlorperazine Maleate Tablets, USP 5mg, 100 ... | Dec 27, 2022 |
| D-1293-2022 | Class II | Irbesartan Tablets, USP, 150mg, 90- count bottl... | Jul 18, 2022 |
| D-1294-2022 | Class II | Irbesartan Tablets, USP, 75 mg, 90- count bottl... | Jul 18, 2022 |
| D-0752-2022 | Class III | Methylprednisolone Tablets, USP 4mg, 100-count ... | Apr 1, 2022 |
| D-0767-2022 | Class I | Meclizine Hydrochloride Tablets USP, 12.5 mg, p... | Mar 8, 2022 |
Frequently Asked Questions
Stop taking the medication and contact your pharmacist or doctor immediately. For Class I recalls, this is urgent. For Class II or III recalls, consult your doctor before stopping — abruptly discontinuing certain medications (blood pressure drugs, antidepressants, diabetes medications) can be more harmful than continuing while arranging a replacement. Check whether the recall applies to your specific lot number and expiration date. Return the product to your pharmacy and report any adverse effects to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.